Advertisement
U.S. markets closed
  • S&P 500

    5,160.64
    -49.27 (-0.95%)
     
  • Dow 30

    38,461.51
    -422.16 (-1.09%)
     
  • Nasdaq

    16,170.36
    -136.28 (-0.84%)
     
  • Russell 2000

    2,028.39
    -52.41 (-2.52%)
     
  • Crude Oil

    86.25
    +1.02 (+1.20%)
     
  • Gold

    2,352.00
    -10.40 (-0.44%)
     
  • Silver

    28.03
    +0.05 (+0.18%)
     
  • EUR/USD

    1.0747
    -0.0112 (-1.03%)
     
  • 10-Yr Bond

    4.5600
    +0.1940 (+4.44%)
     
  • GBP/USD

    1.2538
    -0.0139 (-1.10%)
     
  • USD/JPY

    153.0030
    +1.2480 (+0.82%)
     
  • Bitcoin USD

    69,897.34
    +847.89 (+1.23%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,961.21
    +26.42 (+0.33%)
     
  • Nikkei 225

    39,581.81
    -191.32 (-0.48%)
     

IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Endologix, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 20, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Endologix, Inc. ("Endologix" or the "Company") (ELGX) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired Endologix shares between August 2, 2016 and November 16, 2016 inclusive (the "Class Period"), are encouraged to contact the firm prior to March 6, 2017, also known as the lead plaintiff motion deadline.

To participate in this class action lawsuit, call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

Nellix is Endologix's endovascular aneurysm sealing system used against infrarenal abdominal aortic aneurysms. Endologix allowed the Nellix system to be applied in the Nellix investigational device exemption (IDE) clinical trial, the EVAS FORWARD-IDE Study. However, Endologix revealed that the FDA asked for a follow-up on patients in the EVAS-FORWARD-IDE study to measure Nellix. On December 27, 2016 Endologix revealed that it was barring AFX Endovascular AAA System shipments indefinitely because of a manufacturing investigation. When this news was shared with the investing public, Endologix stock fell, causing shareholders serious harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com

SOURCE: Lundin Law PC

Advertisement